Matsuda H, Shoemaker W C
Arch Surg. 1975 Mar;110(3):301-5. doi: 10.1001/archsurg.1975.01360090071015.
Cardiorespiratory effects of dextran 40 administration were measured and compared retrospectively in 74 surviving and 73 nonsurviving critically ill patients. In the preinfusion control period, the survivors had higher mean arterial pressures and blood flow with lesser blood volume deficits. Dextran significantly improved pressure, blood flow, blood volume, oxygen transport, and derived calculations in both groups, but the average cardiorespiratory responses to dextran were somewhat greater in nonsurvivors than in survivors, About two thirds of the patients responded to dextran with significantly increased oxygen consumption (P smaller than .05), suggesting that this agent improved oxygen transport by its rheologic effects on the microcirculation. The cardiorespiratory effects of dextran were slightly greater in the patients who ultimately died; nevertheless, the salutary cardiorespiratory response did not reverse the clinical course in nonsurvivors, whose perfusion defect apparently had reached irreversible proportions prior to the administration of the drug.
对74名存活和73名未存活的重症患者回顾性测量并比较了给予右旋糖酐40后的心肺效应。在输注前的对照期,存活者平均动脉压和血流量较高,血容量不足较少。右旋糖酐显著改善了两组的血压、血流量、血容量、氧输送及相关计算指标,但未存活者对右旋糖酐的平均心肺反应略大于存活者。约三分之二的患者对右旋糖酐有显著增加的氧耗(P小于0.05),提示该药物通过对微循环的流变学作用改善了氧输送。最终死亡患者对右旋糖酐的心肺效应略大;然而,有益的心肺反应并未逆转未存活者的临床病程,其灌注缺陷在用药前显然已达到不可逆程度。